In our latest eBook we are exploring the current status of cancer immunotherapy within the clinic and looking at what is next for this therapeutic modality. Key topics covered in this eBook include the management of therapy-related toxicities, the optimization of immunotherapy and how we can overcome treatment resistance.
Highlights include:
- [COMMENTARY] Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
- [META-ANALYSIS] Immune-related adverse events with PD-1 vs PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
- [PANEL DISCUSSION] Past, present and future of immuno-oncology
- [EDITORIAL] Immuno-oncology: what have been the top advancements in 2021?
- [INFOGRAPHIC] The future of immuno-oncology
